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Abstract Metabolic models can provide a mechanistic
framework to analyze information-rich omics data sets, and
are increasingly being used to investigate metabolic alter-
nations in human diseases. An expression of the altered
metabolic pathway utilization is the selection of metabo-
lites consumed and released by cells. However, methods
for the inference of intracellular metabolic states from
extracellular measurements in the context of metabolic
models remain underdeveloped compared to methods for
other omics data. Herein, we describe a workflow for such
an integrative analysis emphasizing on extracellular met-
abolomics data. We demonstrate, using the lymphoblastic
leukemia cell lines Molt-4 and CCRF-CEM, how our
methods can reveal differences in cell metabolism. Our
models explain metabolite uptake and secretion by pre-
dicting a more glycolytic phenotype for the CCRF-CEM
model and a more oxidative phenotype for the Molt-4
model, which was supported by our experimental data.
Gene expression analysis revealed altered expression of
gene products at key regulatory steps in those central
metabolic pathways, and literature query emphasized the
role of these genes in cancer metabolism. Moreover,
in silico gene knock-outs identified unique control points
for each cell line model, e.g., phosphoglycerate dehydro-
genase for the Molt-4 model. Thus, our workflow is well-
suited to the characterization of cellular metabolic traits
based on extracellular metabolomic data, and it allows the
integration of multiple omics data sets into a cohesive
picture based on a defined model context.
Keywords Constraint-based modeling  Metabolomics 
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1 Introduction
Modern high-throughput techniques have increased the
pace of biological data generation. Also referred to as the
‘‘omics avalanche’’, this wealth of data provides great
opportunities for metabolic discovery. Omics data sets
contain a snapshot of almost the entire repertoire of
mRNA, protein, or metabolites at a given time point or
under a particular set of experimental conditions. Because
of the high complexity of the data sets, computational
modeling is essential for their integrative analysis. Cur-
rently, such data analysis is a bottleneck in the research
process and methods are needed to facilitate the use of
these data sets, e.g., through meta-analysis of data available
in public databases [e.g., the human protein atlas (Uhlen
et al. 2010) or the gene expression omnibus (Barrett et al.
Electronic supplementary material The online version of this
article (doi:10.1007/s11306-014-0721-3) contains supplementary
material, which is available to authorized users.
M. K. Aurich  G. Paglia  O´. Rolfsson  S. Hrafnsdo´ttir 
M. Magnu´sdo´ttir  B. Ø. Palsson  R. M. T. Fleming  I. Thiele
Center for Systems Biology, University of Iceland, Reykjavik,
Iceland
M. K. Aurich  R. M. T. Fleming  I. Thiele (&)
Luxembourg Centre for Systems Biomedicine, University of
Luxembourg, Campus Belval, Esch-Sur-Alzette, Luxembourg
e-mail: ines.thiele@uni.lu
M. M. Stefaniak
School of Health Science, Faculty of Food Science and
Nutrition, University of Iceland, Reykjavik, Iceland
B. Ø. Palsson
Department of Bioengineering, University of California San
Diego, La Jolla, CA, USA
123
Metabolomics (2015) 11:603–619
DOI 10.1007/s11306-014-0721-3
2011)], and to increase the accessibility of valuable infor-
mation for the biomedical research community.
Constraint-based modeling and analysis (COBRA) is a
computational approach that has been successfully used to
investigate and engineer microbial metabolism through the
prediction of steady-states (Durot et al. 2009). The basis of
COBRA is network reconstruction: networks are assembled
in a bottom-up fashion based on genomic data and extensive
organism-specific information from the literature. Metabolic
reconstructions capture information on the known bio-
chemical transformations taking place in a target organism to
generate a biochemical, genetic and genomic knowledge
base (Reed et al. 2006). Once assembled, a metabolic
reconstruction can be converted into a mathematical model
(Thiele and Palsson 2010), and model properties can be
interrogated using a great variety of methods (Schellenber-
ger et al. 2011). The ability of COBRA models to represent
genotype–phenotype and environment–phenotype relation-
ships arises through the imposition of constraints, which
limit the system to a subset of possible network states (Lewis
et al. 2012). Currently, COBRA models exist for more than
100 organisms, including humans (Duarte et al. 2007; Thiele
et al. 2013).
Since the first human metabolic reconstruction was
described [Recon 1 (Duarte et al. 2007)], biomedical appli-
cations of COBRA have increased (Bordbar and Palsson
2012). One way to contextualize networks is to define their
system boundaries according to the metabolic states of the
system, e.g., disease or dietary regimes. The consequences of
the applied constraints can then be assessed for the entire
network (Sahoo and Thiele 2013). Additionally, omics data
sets have frequently been used to generate cell-type or con-
dition-specific metabolic models. Models exist for specific
cell types, such as enterocytes (Sahoo and Thiele 2013),
macrophages (Bordbar et al. 2010), and adipocytes (Mar-
dinoglu et al. 2013), and even multi-cell assemblies that
represent the interactions of brain cells (Lewis et al. 2010).
All of these cell type specific models, except the enterocyte
reconstruction were generated based on omics data sets.
Cell-type-specific models have been used to study diverse
human disease conditions. For example, an adipocyte model
was generated using transcriptomic, proteomic, and meta-
bolomics data. This model was subsequently used to inves-
tigate metabolic alternations in adipocytes that would allow
for the stratification of obese patients (Mardinoglu et al.
2013). One highly active field within the biomedical appli-
cations of COBRA is cancer metabolism (Jerby and Ruppin,
2012). Omics-driven large-scale models have been used to
predict drug targets (Folger et al. 2011; Jerby et al. 2012). A
cancer model was generated using multiple gene expression
data sets and subsequently used to predict synthetic lethal
gene pairs as potential drug targets selective for the cancer
model, but non-toxic to the global model (Recon 1), a
consequence of the reduced redundancy in the cancer spe-
cific model (Folger et al. 2011). In a follow up study, lethal
synergy between FH and enzymes of the heme metabolic
pathway were experimentally validated and resolved the
mechanism by which FH deficient cells, e.g., in renal-cell
cancer cells survive a non-functional TCA cycle (Frezza
et al. 2011).
Contextualized models, which contain only the subset of
reactions active in a particular tissue (or cell-) type, can be
generated in different ways (Becker and Palsson, 2008; Jerby
et al. 2010). However, the existing algorithms mainly con-
sider gene expression and proteomic data to define the reac-
tion sets that comprise the contextualized metabolic models.
These subset of reactions are usually defined based on the
expression or absence of expression of the genes or proteins
(present and absent calls), or inferred from expression values
or differential gene expression. Comprehensive reviews of
the methods are available (Blazier and Papin, 2012; Hyduke
et al. 2013). Only the compilation of a large set of omics data
sets can result in a tissue (or cell-type) specific metabolic
model, whereas the representation of one particular experi-
mental condition is achieved through the integration of omics
data set generated from one experiment only (condition-
specific cell line model). Recently, metabolomic data sets
have become more comprehensive and using these data sets
allow direct determination of the metabolic network com-
ponents (the metabolites). Additionally, metabolomics has
proven to be stable, relatively inexpensive, and highly
reproducible (Antonucci et al. 2012). These factors make
metabolomic data sets particularly valuable for interrogation
of metabolic phenotypes. Thus, the integration of these data
sets is now an active field of research (Li et al. 2013; Mo et al.
2009; Paglia et al. 2012b; Schmidt et al. 2013). Generally,
metabolomic data can be incorporated into metabolic net-
works as qualitative, quantitative, and thermodynamic con-
straints (Fleming et al. 2009; Mo et al. 2009). Mo et al. used
metabolites detected in the spent medium of yeast cells to
determine intracellular flux states through a sampling ana-
lysis (Mo et al. 2009), which allowed unbiased interrogation
of the possible network states (Schellenberger and Palsson
2009) and prediction of internal pathway use. Such analyses
have also been used to reveal the effects of enzymopathies on
red blood cells (Price et al. 2004), to study effects of diet on
diabetes (Thiele et al. 2005) and to define macrophage met-
abolic states (Bordbar et al. 2010). This type of analysis is
available as a function in the COBRA toolbox (Schellen-
berger et al. 2011).
In this study, we established a workflow for the gener-
ation and analysis of condition-specific metabolic cell line
models that can facilitate the interpretation of metabolomic
data. Our modeling yields meaningful predictions regard-
ing metabolic differences between two lymphoblastic leu-
kemia cell lines (Fig. 1A).
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2 Results
We set up a pipeline that could be used to infer intracellular
metabolic states from semi-quantitative data regarding
metabolites exchanged between cells and their environ-
ment. Our pipeline combined the following four steps: data
acquisition, data analysis, metabolic modeling and exper-
imental validation of the model predictions (Fig. 1A). We
demonstrated the pipeline and the predictive potential to
predict metabolic alternations in diseases such as cancer
based on two lymphoblastic leukemia cell lines. The
resulting Molt-4 and CCRF-CEM condition-specific cell
Fig. 1 A Combined experimental and computational pipeline to
study human metabolism. Experimental work and omics data analysis
steps precede computational modeling. Model predictions are
validated based on targeted experimental data. Metabolomic and
transcriptomic data are used for model refinement and submodel
extraction. Functional analysis methods are used to characterize the
metabolism of the cell-line models and compare it to additional
experimental data. The validated models are subsequently used for the
prediction of drug targets. B Uptake and secretion pattern of model
metabolites. All metabolite uptakes and secretions that were mapped
during model generation are shown. Metabolite uptakes are depicted
on the left, and secreted metabolites are shown on the right. A number
of metabolite exchanges mapped to the model were unique to one cell
line. Differences between cell lines were used to set quantitative
constraints for the sampling analysis. C Statistics about the cell line-
specific network generation. D Quantitative constraints. For the
sampling analysis, an additional set of constraints was imposed on the
cell line specific models, emphasizing the differences in metabolite
uptake and secretion between cell lines. Higher uptake of a metabolite
was allowed in the model of the cell line that consumed more of the
metabolite in vitro, whereas the supply was restricted for the model
with lower in vitro uptake. This was done by establishing the same
ratio between the models bounds as detected in vitro. X denotes the
factor (slope ratio) that distinguishes the bounds, and which was
individual for each metabolite. (a) The uptake of a metabolite could
be x times higher in CCRF-CEM cells, (b) the metabolite uptake
could be x times higher in Molt-4, (c) metabolite secretion could be x
times higher in CCRF-CEM, or (d) metabolite secretion could be x
times higher in Molt-4 cells. LOD limit of detection. The consequence
of the adjustment was, in case of uptake, that one model was
constrained to a lower metabolite uptake (A, B), and the difference
depended on the ratio detected in vitro. In case of secretion, one
model had to secrete more of the metabolite, and again the difference
depended on the experimental difference detected between the cell
lines
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line models were able to explain metabolite uptake and
secretion by predicting the distinct utilization of central
metabolic pathways by the two cell lines. Whereas the
CCRF-CEM model resembled more a glycolytic, com-
monly referred to as ‘Warburg’ phenotype, suggested our
predictions a more respiratory phenotype for the Molt-4
model. We found these predictions to be in agreement with
measured gene expression differences at key regulatory
steps in the central metabolic pathways, and they were also
consistent with additional experimental data regarding the
energy and redox states of the cells. After a brief discussion
of the data generation and analysis steps, the results
derived from model generation and analysis will be
described in detail.
2.1 Pipeline for generation of condition-specific
metabolic cell line models
2.1.1 Generation of experimental data
We monitored the growth and viability of lymphoblastic
leukemia cell lines in serum-free medium (File S2,
Fig. S1). Multiple omics data sets were derived from these
cells. Extracellular metabolomics (exo-metabolomic) data,
comprising measurements of the metabolites in the spent
medium of the cell cultures (Paglia et al. 2012a), were
collected along with transcriptomic data, and these data
sets were used to construct the models.
2.1.2 Analysis of experimental data
Data analysis included defining the sets of metabolites that
were taken up or secreted (qualitatively for the generation
of the models), and it included determining the quantitative
differences in uptake and secretion between cell lines
(Fig. 1B). These differences were later subjected to model
constraints. The final sets of metabolite exchanges that
were used for model generation comprised the uptake and
secretion of 14 and 10 metabolites by both models, unique
secretion of 7 and unique uptake of 4 metabolites by the
CCRF-CEM model, and secretion of 1 and uptake of 1
unique metabolite in Molt-4 cells (Fig. 1B). Additionally,
sets of genes treated as expressed and unexpressed (absent
and present calls), and groups of differentially expressed
genes (DEGs) and alternatively spliced genes (AS) were
predicted by comparing expression in CCRF-CEM and
Molt-4 cells (see ‘‘Materials and methods’’ section and File
S2 in supplementary information for more detail).
2.1.3 Generation of condition-specific cell line models
Model generation involves three steps: refinement of the
global model, data mapping and submodel extraction. We
added transport and exchange reactions for metabolites that
could not be transported between the extracellular space
and the cytosol (see ‘‘Materials and methods’’ section).
Nutrient supply (for metabolite uptake) was restricted to
the RPMI medium composition (File S1, Table S1).
First, the detected metabolite uptakes and secretions for
each cell line were mapped separately to the model. The
model was thereby constrained to represent a minimal set
of metabolite exchange reactions required to support all of
the observed metabolite uptakes and secretions and to
explain the experimentally observed growth rates of the
cells (Fig. 1B, File S1, Tables S2–S3). The result was a
vast reduction of the number of possible metabolite uptakes
and secretions in the two preliminary models (Fig. 1C),
which placed major emphasis on the experimentally
observed metabolite uptake and secretion profiles.
In addition to the (qualitative) exo-metabolomic con-
straints, genomic data were mapped to the preliminary
models (File S1, Table S4). In general, the mapping of
transcriptomic data, which meant the deletion of all reac-
tions associated with the set of absent genes, and which
was performed after the integration of the exo-metabolo-
mic data, did not prevent that either model could represent
the detected metabolite uptake, metabolite secretion, or
biomass production. Curation beyond the initial definition
of the minimal sets of mandatory exchanges was therefore
not necessary.
Subsequently, the condition-specific CCRF-CEM and
Molt-4 models were extracted through network pruning.
Model reactions unable to support flux were identified
through flux variability analysis (FVA) and removed,
leaving the functional reaction sets to compose the final
Molt-4 and CCRF-CEM models.
2.1.4 Condition-specific models for CCRF-CEM and Molt-
4 cells
To determine whether we had obtained two distinct mod-
els, we evaluated the reactions, metabolites, and genes of
the two models. Both the Molt-4 and CCRF-CEM models
contained approximately half of the reactions and metab-
olites present in the global model (Fig. 1C). They were
very similar to each other in terms of their reactions,
metabolites, and genes (File S1, Table S5A–C). The Molt-
4 model contained seven reactions that were not present in
the CCRF-CEM model (Co-A biosynthesis pathway and
exchange reactions). In contrast, the CCRF-CEM contained
31 unique reactions (arginine and proline metabolism,
vitamin B6 metabolism, fatty acid activation, transport, and
exchange reactions). There were 2 and 15 unique metab-
olites in the Molt-4 and CCRF-CEM models, respectively
(File S1, Table S5B). Approximately three quarters of the
global model genes remained in the condition-specific cell
606 M. K. Aurich et al.
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line models (Fig. 1C). The Molt-4 model contained 15
unique genes, and the CCRF-CEM model had 4 unique
genes (File S1, Table S5C). Both models lacked NADH
dehydrogenase (complex I of the electron transport chain—
ETC), which was determined by the absence of expression
of a mandatory subunit (NDUFB3, Entrez gene ID 4709).
Rather, the ETC was fueled by FADH2 originating from
succinate dehydrogenase and from fatty acid oxidation,
which through flavoprotein electron transfer could con-
tribute to the same ubiquinone pool as complex I and
complex II (succinate dehydrogenase). Despite their dif-
ferent in vitro growth rates (which differed by 11 %, see
File S2, Fig. S1) and differences in exo-metabolomic data
(Fig. 1B) and transcriptomic data, the internal networks
were largely conserved in the two condition-specific cell
line models.
2.1.5 Condition-specific cell line models predict distinct
metabolic strategies
Despite the overall similarity of the metabolic models,
differences in their cellular uptake and secretion patterns
suggested distinct metabolic states in the two cell lines
(Fig. 1B and see ‘‘Materials and methods’’ section for more
detail). To interrogate the metabolic differences, we sam-
pled the solution space of each model using an Artificial
Centering Hit-and-Run (ACHR) sampler (Thiele et al.
2005). For this analysis, additional constraints were
applied, emphasizing the quantitative differences in com-
monly uptaken and secreted metabolites. The maximum
possible uptake and maximum possible secretion flux rates
were reduced according to the measured relative differ-
ences between the cell lines (Fig. 1D, see ‘‘Materials and
methods’’ section).
We plotted the number of sample points containing a
particular flux rate for each reaction. The resulting binned
histograms can be understood as representing the proba-
bility that a particular reaction can have a certain flux
value. A comparison of the sample points obtained for the
Molt-4 and CCRF-CEM models revealed a considerable
shift in the distributions, suggesting a higher utilization of
glycolysis by the CCRF-CEM model (File S2, Fig. S2).
This result was further supported by differences in medians
calculated from sampling points (File S1, Table S6). The
shift persisted throughout all reactions of the pathway and
was induced by the higher glucose uptake (35 %) from the
extracellular medium in CCRF-CEM cells. The sampling
median for glucose uptake was 34 % higher in the CCRF-
CEM model than in Molt-4 model (File S2, Fig. S2).
The usage of the TCA cycle was also distinct in the two
condition-specific cell-line models (Fig. 2). Interestingly,
the models used succinate dehydrogenase differently
(Figs. 2, 3). The Molt-4 model utilized an associated
reaction to generate FADH2, whereas in the CCRF-CEM
model, the histogram was shifted in the opposite direction,
toward the generation of succinate. Additionally, there was
a higher efflux of citrate toward amino acid and lipid
metabolism in the CCRF-CEM model (Fig. 2). There was
higher flux through anaplerotic and cataplerotic reactions
in the CCRF-CEM model than in the Molt-4 model
(Fig. 2); these reactions include the efflux of citrate
through ATP-citrate lyase, uptake of glutamine, generation
of glutamate from glutamine, transamination of pyruvate
and glutamate to alanine and to 2-oxoglutarate, secretion of
nitrogen, and secretion of alanine. The Molt-4 model
showed higher utilization of oxidative phosphorylation
(Fig. 3), again supported by elevated median flux through
ATP synthase (36 %) and other enzymes, which contrib-
uted to higher oxidative metabolism. The sampling analysis
therefore revealed different usage of central metabolic
pathways by the condition-specific models.
2.1.6 Experimental validation of energy and redox status
of CCRF-CEM and Molt-4 cells
Cancer cells have to balance their needs for energy and
biosynthetic precursors, and they have to maintain redox
homeostasis to proliferate (Cairns et al. 2011). We con-
ducted enzymatic assays of cell lysates to measure levels
and/or ratios of ATP, NADPH ? NADP, NADH ? NAD,
and glutathione. These measurements were used to provide
support for the in silico predicted metabolic differences
(Fig. 4). Additionally, an Oxygen Radical Absorbance
Capacity (ORAC) assay was used to evaluate the cellular
antioxidant status (Fig. 4B). Total concentrations of
NADH ? NAD, GSH ? GSSG, NADPH ? NADP and
ATP, were higher in Molt-4 cells (Fig. 4A). The higher
ATP concentration in Molt-4 cells could either result from
high production rates, or intracellular accumulation con-
nected to high or low reactions fluxes (Fig. 4A). Our
simplified view that oxidative Molt-4 produces less ATP
and was contradicted by the higher ATP concentrations
measured (Fig. 4L). Yet we want to emphasize that con-
centrations cannot be compared to flux values, since we are
modeling at steady-state. NADH/NAD? ratios for both
cell lines were shifted toward NADH (Fig. 4D, E), but the
shift toward NADH was more pronounced in CCRF-CEM
(Fig. 4E), which matched our expectation based on the
higher utilization of glycolysis and 2-oxoglutarate dehy-
drogenase in the CCRF-CEM model (Fig. 4L).
The mitochondrial membrane has been suggested to be
the quantitatively most important physiological source of
superoxide in higher organisms (Chance et al. 1979). If the
Molt-4 cells were relying more on mitochondrial respira-
tion, we expected them to counteract the increased oxida-
tive stress by using antioxidant systems such as glutathione
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and NADPH (Fig. 4L). Indeed, Molt-4 cells showed a
higher capacity for reactive oxygen species (ROS) detox-
ification than CCRF-CEM cells (Fig. 4B), which was
supported by the higher utilization of oxidative
phosphorylation and spermidine dismutase by the Molt-4
model (SPODM, median CCRF-CEM = 0.0010 U, and
Molt-4 = 0.0011 U) (Fig. 4L). Reduced glutathione
(GSH) is of major importance for the clearance of ROS
(Droge 2002). GSH/GSSG ratios were shifted toward GSH
in both cell lines (CCRF-CEM = 747:51, Molt-
4 = 1182:56), and the shift was more pronounced in Molt-
4 cells (Fig. 4K).
Both cell lines had low NADPH/NADP? ratios (CCRF-
CEM 4.7:2.8, Molt-4 6:11.5). However, in Molt-4 cells, the
ratio was shifted toward NADP?, whereas CCRF-CEM
cells contained higher amounts of NADPH (Fig. 4G, H).
This matched our expectation that the glycolytic CCRF-
CEM model would produce more NADPH (Fig. 4L) and
that it would exhibit higher flux through the oxidative
phase of the pentose phosphate pathway (PPP). Taken
bFig. 2 Differences in the use of the TCA cycle by the CCRF-CEM
model (red) and the Molt-4 model (blue). The table provides the
median values of the sampling results. Negative values in histograms
and in the table describe reversible reactions with flux in the reverse
direction. There are multiple reversible reactions for the transforma-
tion of isocitrate and a-ketoglutarate, malate and fumarate, and
succinyl-CoA and succinate. These reactions are unbounded, and
therefore histograms are not shown. The details of participating
cofactors have been removed. Atp ATP, cit citrate, adp ADP, pi
phosphate, oaa oxaloacetate, accoa acetyl-CoA, coa coenzyme-A, icit
isocitrate, akg a-ketoglutarate, succ-coa succinyl-CoA, succ succi-
nate, fum fumarate, mal malate, oxa oxaloacetate, pyr pyruvate, lac
lactate, ala alanine, gln glutamine, ETC electron transport chain
Fig. 3 Sampling reveals different utilization of oxidative phosphory-
lation by the generated models. Different distributions are observed for
the CCRF-CEM model (red) and the Molt-4 model (blue). Molt-4 has
higher median flux through ETC reactions II–IV. The table provides the
median values of the sampling results. Negative values in the
histograms and in the table describe reversible reactions with flux in
the reverse direction. Both models lack Complex I of the ETC because
of constraints arising from the mapping of transcriptomic data. Electron
transfer flavoprotein and electron transfer flavoprotein–ubiquinone
oxidoreductase both also carry higher flux in the Molt-4 model
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together, the experimental data agreed well with our
expectations based on the predicted phenotypes. We sought
additional support for the predicted metabolic differences
in the transcriptomic data.
2.1.7 Comparison of network utilization and alteration
in gene expression
With the assumption that differential expression of partic-
ular genes would cause reaction flux changes, we deter-
mined how the differences in gene expression (between
CCRF-CEM and Molt-4) compared to the flux differences
observed in the models. Specifically, we checked whether
the reactions associated with genes upregulated (signifi-
cantly more expressed in CCRF-CEM cells compared to
Molt-4 cells) were indeed more utilized by the CCRF-CEM
model, and we checked whether downregulated genes were
associated with reactions more utilized by the Molt-4
model.
The set of downregulated genes was associated with 15
reactions, and the set of 49 upregulated genes was associ-
ated with 113 reactions in the models. Reactions were
Fig. 4 A–K Experimentally
determined ATP, NADH ? NAD,
NADPH ? NADP, and
GSH ? GSSG concentrations, and
ROS detoxification in the CCRF-
CEM and Molt-4 cells.
L Expectations for cellular energy
and redox states. Expectations are
based on predicted metabolic
differences of the Molt-4 and
CCRF-CEM models
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defined as differently utilized if the difference in flux
exceeded 10 % (considering only non-loop reactions). Of
the reactions associated with upregulated genes, 72.57 %
were more utilized by the CCRF-CEM model, and 2.65 %
were more utilized by the Molt-4 model (File S1,
Table S7). In contrast, all 15 reactions associated with the
12 downregulated genes were more utilized in the CCRF-
CEM model (File S1, Table S8). After this initial analysis,
we approached the question from a different angle, asking
whether the majority of the reactions associated with each
individual gene upregulated in CCRF-CEM were more
utilized by the CCRF-CEM model. We found that this was
the case for 77.55 % of the upregulated genes. The
majority of reactions associated with two (16.67 %)
downregulated genes were more utilized by the Molt-4
model. Taken together, our comparisons of the direction of
gene expression with the fluxes of the two cancer cell-line
models confirmed that reactions associated with upregu-
lated genes in the CCRF-CEM cells were generally more
utilized by the CCRF-CEM model.
2.1.8 Accumulation of DEGs and AS genes at key
metabolic steps
After we confirmed that most reactions associated with
upregulated genes were more utilized by the CCRF-CEM
model, we checked the locations of DEGs within the net-
work. In this analysis, we paid special attention to the
central metabolic pathways that we had found to be dis-
tinctively utilized by the two models. Several DEGs and
AS events were associated with glycolysis, the ETC,
pyruvate metabolism, and the PPP (Table 1).
Moreover, in glycolysis, the DEGs and/or AS genes
were associated with all three rate-limiting steps, i.e., the
steps mediated by hexokinase, pyruvate kinase, and phos-
phofructokinase. Of these key enzymes, hexokinase 1
(Entrez Gene ID: 3098) was alternatively spliced, and
pyruvate kinase (PKM, Entrez gene ID: 5315) was signif-
icantly more expressed in the CCRF-CEM cells (Table 1),
in agreement with the higher in silico predicted flux.
However, in contrast to the observed higher utilization of
glycolysis in the CCRF-CEM model, we found that the
gene associated with the rate-limiting glycolysis step,
phosphofructokinase (Entrez Gene ID: 5213), was signifi-
cantly upregulated in Molt-4 cells relative to CCRF-CEM
cells. This higher expression was detected for only a single
isozyme, however. Two of the three genes associated with
phosphofructokinase were also subject to alternative
splicing (Table 1). In addition to the key enzymes, fructose
bisphosphate aldolase (Entrez Gene ID: 230) was also
significantly upregulated in Molt-4 cells relative to CCRF-
CEM cells, which was in contrast to the predicted higher
utilization of glycolysis in the CCRF-CEM model.
Additionally, glucose-6P-dehydrogenase (G6PD), which
catalyzes the first reaction and commitment step of the
PPP, was an AS gene (Table 1). A second AS gene asso-
ciated with the PPP reaction of the deoxyribokinase was
RBKS (Entrez Gene ID: 64080). This gene is also associ-
ated with ribokinase, but ribokinase was removed during
model construction because of the lack of ribose uptake or
secretion. Single AS genes were associated with different
complexes of the ETC (Table 1). Literature query revealed
that at least 13 genes associated with alternative splicing
events were mentioned previously in connection with both
alternative splicing and cancer (File S1, Table S14), and 37
genes were associated with cancer, e.g., upregulated,
downregulated at the level of mRNA or protein, or other-
wise connected to cancer metabolism and signaling. One
general observation was that there was a surprising accu-
mulation of metabolite transporters among the AS.
Overall, the high incidence of differential gene expres-
sion events at metabolic control points increases the plau-
sibility of the in silico predictions.
2.1.9 Single gene deletion
Analyses of essential genes in metabolic models have been
used to predict candidate drug targets for cancer cells
(Folger et al. 2011). Here, we conducted an in silico gene
deletion study for all model genes to identify a unique set
of knock-out (KO) genes for each condition-specific cell
line model. The analysis yielded 63 shared lethal KO genes
and distinct sets of KO genes for the CCRF-CEM model
(11 genes) and the Molt-4 model (3 genes). For three of the
unique CCRF-CEM KO genes, the genes were only present
in the CCRF-CEM model (File S1, Table S9).
The essential genes for both models were then related to
the cell-line-specific differences in metabolite uptake and
secretion (Fig. 1B). The CCRF-CEM model needed to
generate putrescine from ornithine (ORNDC, Entrez Gene
ID: 4953) to subsequently produce 5-methylthioadenosine
for secretion (Fig. 1B). S-adenosylmethioninamine pro-
duced by adenosylmethionine decarboxylase (arginine and
proline metabolism, associated with Entrez Gene ID: 262)
is a substrate required for generation of 5-methylthioa-
denosine. Another example of a KO gene connected to an
enforced exchange reaction was glutamic-oxaloacetic
transaminase 1 (GOT1, Entrez Gene ID: 2805). Without
GOT1, the CCRF-CEM model was forced to secrete
4-hydroxyphenylpyruvate (Fig. 1B), the second product of
tyrosine transaminase, which is produced only by that
enzyme.
One KO gene in the Molt-4 model (Entrez Gene ID:
26227) was associated with phosphoglycerate dehydroge-
nase (PGDH), which catalyzes the conversion of 3-phos-
pho-D-glycerate to 3-phosphohydroxypyruvate while
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generating NADH from NAD?. This KO gene is particu-
larly interesting, given the involvement of this reaction in a
novel pathway for ATP generation in rapidly proliferating
cells (Locasale et al. 2011; Vander Heiden 2011; Vazquez
et al. 2011). Reactions associated with unique KO genes
were in many cases utilized more by the model, in which
the gene KO was lethal, underlining the potential impor-
tance of these reactions for the models. Thus, single gene
deletion provided unique sets of lethal genes that could be
specifically targeted to kill these cells.
3 Discussion
In the current study, we explored the possibility of semi-
quantitatively integrating metabolomic data with the
human genome-scale reconstruction to facilitate analysis.
By constructing condition-specific cell line models to
provide a structured framework, we derived insights that
could not have been obtained from data analysis alone.
We derived condition-specific cell line models for
CCRF-CEM and Molt-4 cells that were able to explain the
observed exo-metabolomic differences (Fig. 1B). Despite
the overall similarities between the models, the analysis
revealed distinct usage of central metabolic pathways
(Figs. 2, 3, 4), which we validated based on experimental
data and differential gene expression. The additional data
sufficiently supported metabolic differences in these cell
lines, providing confidence in the generated models and the
model-based predictions. We used the validated models to
predict unique sets of lethal genes to identify weak links in
each model. These weak links may represent potential drug
targets.
Integrating omics data with the human genome-scale
reconstruction provides a structured framework (i.e.,
pathways) that is based on careful consideration of the
Table 1 DEGs and AS events of central metabolic and cancer-related pathways
DEG associated
reactions
Median Molt-4
(mmol/gdw/h)
Median CCRF-CEM
(mmol/gdw/h)
Entrez
Gene ID
Direction
change
Subsystem AS Entrez
Gene ID
ALDD2xm 0.040 0.051 219 Upregulated Glycolysis/glucon.
FBA 12.898 18.800 230 Downregulated Glycolysis/glucon.
G3PD2 m 0.068 0.191 2820 Upregulated Glycolysis/glucon.
PYK 36.115 54.746 5315 Upregulated Glycolysis/glucon.
ALDD2x 0.035 0.050 223 Upregulated Glycolysis/glucon. 8854
ALDD2y 0.039 0.052 223 Upregulated Glycolysis/glucon. 8854
G6PPer 0.099 0.138 92579 Upregulated Glycolysis/glucon. 92579
PDHm 0.351 0.162 1737 Upregulated Glycolysis/glucon. 1737
PFK 13.041 18.995 5213 Downregulated Glycolysis/glucon. 5211 5213
HEX1 6.217 9.835 Glycolysis/glucon. 3098
PGK -36.230 -54.935 Glycolysis/glucon. 5230
ALCD21_D 326.100 327.300 284273 Upregulated Pyruvate met. 284273
ALCD21_L 129.365 128.372 284273 Upregulated Pyruvate met. 284273
ALCD22_D 291.679 289.357 284273 Upregulated Pyruvate met. 284273
ALCD22_L 129.260 128.219 284273 Upregulated Pyruvate met. 284273
LCADi 0.073 0.100 223 Upregulated Pyruvate met. 8854
LCADi_D 0.072 0.100 223 Upregulated Pyruvate met. 8854
PCm 0.241 1.300 5091 Downregulated Pyruvate met. 5091
LALDD 338.276 345.473 Pyruvate met. 9380
ME2 m 0.221 0.178 Pyruvate met. 10873
NADH2_u10 m Upregulated OxPhos
ATPS4 m 3.825 2.455 OxPhos 4905
CYOR_u10 m 2.506 1.563 OxPhos 1537
DRBK 0.146 0.196 PPP 64080
G6PDH2r 0.125 0.109 PPP 2539
Full lists of DEGs and AS are provided in the supplementary material. Upregulated significantly more expressed in CCRF-CEM compared to
Molt-4 cells
PPP pentose phosphate pathway, OxPhos oxidative phosphorylation, Glycolysis/glucon glycolysis/gluconeogenesis, Pyruvate met. pyruvate
metabolism
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available biochemical literature (Thiele and Palsson 2010).
This network context can simplify omics data analysis, and
it allows even non-biochemical experts to gain fast and
comprehensive insights into the metabolic aspects of omics
data sets. Compared to transcriptomic data, methods for the
integration and analysis of metabolomic data in the context
of metabolic models are less well established, although it is
an active field of research (Li et al. 2013; Paglia et al.
2012b). In contrast to other studies, our approach empha-
sizes the representation of experimental conditions rather
than the reconstruction of a generic, cell-line-specific net-
work, which would require the combination of data sets
from many experimental conditions and extensive manual
curation. Rather, our way of model construction allowed us
to efficiently assess the metabolic characteristics of cells.
Despite the fact, that only a limited number of exchanged
metabolites can be measured by available metabolomics
platforms and at reasonable time-scale, and that pathways
of measured metabolites might still be unknown to date
(File S1, Tables S2–S3), our methods have the potential to
reveal metabolic characteristics of cells which could be
useful for biomedicine and personalized health. The rea-
sons why some cancers respond to certain treatments and
not others remain unclear, and choosing a treatment for a
specific patient is often difficult (Vander Heiden 2011).
One potential application of our approach could be the
characterization of cancer phenotypes to explore how
cancer cells or other cell types with particular metabolic
characteristics respond to drugs.
The generation of our condition-specific cell line models
involved only limited manual curation, making this
approach a fast way to place metabolomic data into a
network context. Model building mainly involves the rigid
reduction of metabolite exchanges to match the observed
metabolite exchange pattern with as few additional
metabolite exchanges as possible. It should be noted that
this reduction determines, which pathways can be utilized
by the model. Our approach mostly conserved the internal
network redundancy. However, a more significant reduc-
tion may be achieved using different data. Generally, a
trade-off exists between the reduction of the internal net-
work and the increasing number of network gaps that need
to be curated by using additional omics data, such as
transcriptomics and proteomics. One way to prevent the
emergence of network gaps would be to use mapping
algorithms that conserve network functionality, such as
GIMME (Becker and Palsson 2008). However, several
additional methods exist for the integration of transcrip-
tomic data (Blazier and Papin 2012), and which model-
building method is best depends on the available data.
Interestingly, the lack of a significant contribution of our
gene expression data to the reduction of network size
suggests that the use of transcriptomic data is not necessary
to identify distinct metabolic strategies; rather, the inte-
gration of exo-metabolomic data alone may provide suffi-
cient insight. However, sampling of the cell line models
constrained according to the exo-metabolomic profiles
only, or increasing the cutoff for the generation of absent
and present calls (p\ 0.01), did not yield the same insights
as presented herein (File S1, Table S18). Only recently
Gene Inactivation Moderated by Metabolism, Metabolo-
mics and Expression (GIM(3)E) became available, which
enforces minimum turnover of detected metabolites based
on intracellular metabolomics data as well as gene
expression microarray data (Schmidt et al. 2013). In con-
trast to this approach, we emphasized our analysis on the
relative differences in the exo-metabolomic data of two cell
lines. GIM(3)E constitutes another integration method
when the analysis should be emphasized on intracellular
metabolomics data (Schmidt et al. 2013).
The metabolic differences predicted by the models are
generally plausible. Cancers are known to be heterogeneous
(Cairns et al. 2011), and the contribution of oxidative
phosphorylation to cellular ATP production may vary (Zu
and Guppy 2004). Moreover, leukemia cell lines have been
shown to depend on glucose, glutamine, and fatty acids to
varying extents to support proliferation. Such dependence
may cause the cells to adapt their metabolism to the envi-
ronmental conditions (Suganuma et al. 2010). In addition to
identifying supporting data in the literature, we performed
several analyses to validate the models and model predic-
tions. Our expectations regarding the levels and ratios of
metabolites relevant to energy and redox state were largely
met (Fig. 4L). The more pronounced shift of the NADH/
NAD? ratio toward NADH in the CCRF-CEM cells was in
agreement with the predicted Warburg phenotype (Fig. 4),
and the higher lactate secretion in the CCRF-CEM cells
(File S2, Fig. S2) implies an increase in NADH relative to
NAD? (Chiarugi et al. 2012; Nikiforov et al. 2011), again
matching the known Warburg phenotype.
ROS production is enhanced in certain types of cancer
(Droge 2002; Ha et al. 2000), and the generation of ROS is
thought to contribute to mutagenesis, tumor promotion, and
tumor progression (Dreher and Junod 1996; Ha et al.
2000). However, decreased mitochondrial glucose oxida-
tion and a transition to aerobic glycolysis protect cells
against ROS damage during biosynthesis and cell division
(Brand and Hermfisse 1997). The higher ROS detoxifica-
tion capability in Molt-4 cells, in combination with higher
spermidine dismutase utilization by the Molt-4 model
(Fig. 4), provided a consistent picture of the predicted
respiratory phenotype (Fig. 4L).
Control of NADPH maintains the redox potential
through GSH and protects against oxidative stress, yet
changes in the NADPH ratio in response to oxidative
damage are not well understood (Ogasawara et al. 2009).
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Under stress conditions, as assumed for Molt-4 cells, the
NADPH/NADP? ratio is expected to decrease because of
the continuous reduction of GSSG (Fig. 4L), and this was
confirmed in the Molt-4 cells (Fig. 4). The higher amounts
of GSH found in Molt-4 cells in vitro may demonstrate an
additional need for ROS scavengers because of a greater
reliance on oxidative metabolism.
Cancer is related to metabolic reprogramming, which
results from alterations of gene expression and the
expression of specific isoforms or splice forms to support
proliferation (Cortes-Cros et al. 2013; Marin-Hernandez
et al. 2009). The gene expression differences detected
between the two cell lines in the present study supported
the existence of metabolic differences in these cell lines,
particularly because key steps of the metabolic pathways
central to cancer metabolism seemed to be differentially
regulated (Table 1). The detailed analysis of the respective
differences on the pathway fluxes exceeds the scope of this
study, which was to demonstrate the potential of the inte-
gration of exo-metabolomic data into the network context.
We found discrepancies between differential gene reg-
ulation and the flux differences between the two models as
well as the utilization AS gene-associated reaction. This is
not surprising, since analysis of the detailed system is
required to make any further assumptions on the impact
that the differential regulation or splicing might have on
the reaction flux, given that for many of the concerned
enzymes isozymes exist, or only one of multiple subunits
of a protein complex was concerned. Additionally, reaction
fluxes are regulated by numerous post-translational factors,
e.g., protein modification, inhibition through proteins or
metabolites, alter reaction fluxes (Lenzen 2014), which are
out of the scope of constraint-based steady-state modeling.
Rather, the results of the presented approach demonstrate
how the models can be used to generate informed
hypothesis that can guide experimental work.
The combination of our tailored metabolic models and
differential gene expression analysis seems well-suited to
determine the potential drivers involved in metabolic dif-
ferences between cells. Such information could be valuable
for drug discovery, especially when more peripheral met-
abolic pathways are considered. Additionally, statistical
comparisons of gene expression data with sampling-
derived flux data could be useful in future studies (Mar-
dinoglu et al. 2013).
A single-gene-deletion analysis revealed that PGDH was
a lethal KO gene for the Molt-4 model only. Differences in
PGDH protein levels correspond to the amount of glycolytic
carbon diverted into glycine biosynthesis. Rapidly prolif-
erating cells may use an alternative glycolytic pathway for
ATP generation, which may provide an advantage in the
case of extensive oxidative phosphorylation and prolifera-
tion (Locasale et al. 2011; Vander Heiden 2011; Vazquez
et al. 2011). For breast cancer cell lines, variable depen-
dency on the expression of PGDH has already been dem-
onstrated (Locasale et al. 2011). This example of a unique
KO gene demonstrates how in silico gene deletion in met-
abolomics-driven models can identify the metabolic path-
ways used by cancer cells. This approach can provide
valuable information for drug discovery.
In conclusion, our contextualization method produced
metabolic models that agreed in many ways with the vali-
dation data sets. The analyses described in this study have
great potential to reveal the mechanisms of metabolic
reprogramming, not only in cancer cells but also in other
cells affected by diseases, and for drug discovery in general.
4 Materials and methods
4.1 Global model
The model we used (global model) was a subset of Recon 2
(Thiele et al. 2013), which is freely available (http://
humanmetabolism.org/). Transport and exchange reactions
for metabolites identified according to metabolite uptakes
and secretions detected herein were already considered in
the construction of Recon 2. The model captured 19
additional reactions (File S1, Table S10).
4.2 Cell culture
MOLT-4 and CCRF-CEM cells were obtained from ATCC
(CRL-1582 and CCL-119) and grown by standard methods
in RPMI 1640, with 2 mM GlutaMax and 10 % FBS
(Invitrogen; 61870-010, 10108-57), in a humidified incu-
bator at 37 C under 5 % CO2. At least 3 days before
experiments were conducted, cells were introduced to
serum-free medium (Advanced RPMI 1640, containing
2 mM GlutaMax; Invitrogen; 12633-012, 35050-038). The
medium was refreshed the day before starting the experi-
ment. For experiments, cells were centrifuged at 2019g for
5 min and resuspended in serum-free medium containing
DMSO (0.67 %) at a cell concentration of 5 9 105 cells/
mL. The cell suspension was seeded in triplicate, with 1 or
2 mL applied to a 24-well or 12-well plate, respectively. At
the indicated times, the cells were removed by centrifuga-
tion, and the spent medium was frozen at -80 C. Cell
number, size, and viability (Trypan blue exclusion) were
determined by counting cells on a Countess automatic cell
counter (Invitrogen).
4.3 Analysis of the extracellular metabolome
Mass spectrometry analysis of the exo-metabolome was
performed by Metabolon, Inc. (Durham, NC, USA) using
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a standardized analytical platform. In total, 75 extracellular
metabolites were detected in the initial data set for at least
1 of the 2 cell lines (Paglia et al. 2012a). Of these
metabolites, 15 were not part of our global model and were
discarded. Apart from being absent in our global model, an
independent search in HMDB (Wishart et al. 2013)
revealed no pathway information was available for most of
these metabolites (File S1, Tables S2–S3). It should be
noted that metabolites e.g., N-acetylisoleucine, N-acetyl-
methionine or pseudouridine, constitute protein and RNA
degradation products, which were out of the scope of the
metabolic network.
Thiamin (Vitamin B1) was part of the minimal medium
of essential compounds supplied to both models. Ribofla-
vin (Vitamin B2) and Trehalose were excluded since these
compounds cannot be produced by human cells. Erythrose
and fructose were also excluded. In contrast 46 metabolites
that were part of the global model. The data set included
two different time points, which allowed us to treat the
increase/decrease of a metabolite signal between time
points as evidence for uptake or secretion when the change
was greater than 5 % from what was observed in the
control (File S1, Tables S2–S3). We found 12 metabolites
that were taken up by both cell lines and 10 metabolites
that were commonly secreted by both cell lines over the
course of the experiment. Additionally, Molt-4 cells took
up three metabolites not taken up by CCRF-CEM cells, and
secreted one metabolite not secreted by CCRF-CEM cells.
Two of the three uniquely uptaken metabolites were
essential amino acids: valine and methionine. However, it
is unlikely that these metabolites were not taken up by the
CCRF-CEM cells, and the CCRF-CEM model was allowed
to take up this metabolite. Because of this adjustment, no
quantitative constraints were applied for the sampling
analysis either. CCRF-CEM cells had four unique uptaken
and seven unique secreted metabolites (exchange not
detected in Molt-4 cells).
4.4 Network refinement based on exo-metabolic data
Despite its comprehensiveness, the human metabolic
reconstruction is not complete with respect to extracellular
metabolite transporters (Sahoo et al. 2014; Thiele et al.
2013). Accordingly, we identified metabolite transport
systems from the literature for metabolites that were
already part of the global model, but whose extracellular
transport was not yet accounted for. Diffusion reactions
were included whenever a respective transporter could not
be identified. In total, 34 reactions [11 exchange reactions,
16 transport reactions and 7 demand reactions (File S1,
Table S11)] were added to Recon 2 (Thiele et al. 2013),
and 2 additional reactions were added to the global model
(File S1, Table S10).
4.5 Expression profiling
Molt-4 and CCRF-CEM cells were grown in advanced
RPMI 1640 and 2 mM GlutaMax, and the cells were
resuspended in medium containing DMSO (0.67 %) at a
concentration of 5 9 105 cells/mL. The cell suspension
(2 mL) was seeded in 12-well plates in triplicate. After
48 h of growth, the cells were collected by centrifugation
at 2019g for 5 min. Cell pellets were snap-frozen in liquid
N2 and kept frozen until RNA extraction and analysis by
Aros (Aarhus, Denmark).
4.6 Analysis of transcriptomic data
We used the Affymetrix GeneChip Human Exon 1.0 ST
Array to measure whole genome exon expression. We
generated detection above background (DABG) calls using
ROOT (version 22) and the XPS package for R (version
11.1), with Robust Multi-array Analysis summarization.
Calls for data mapping were assigned based on p\ 0.05 as
the cutoff probability to distinguish presence versus
absence for the 1,278 model genes (File S1, Table S12).
Differential gene expression and alternative splicing
analyses were performed by using AltAnalyse software
(v2.02beta) with default options on the raw data files (CEL
files). The Homo sapiens Ensemble 65 database was used,
probe set filtering was kept as DABG p\ 0.05, and non-
log expression\ 70 was used for constitutive probe sets to
determine gene expression levels. For the comparison,
CCRF-CEM was the experimental group and Molt-4 was
the baseline group. The set of DEGs between cell lines was
identified based on a p\ 0.05 FDR cutoff (File S1,
Table S13A–B). Alternative splicing analysis was per-
formed on core probe sets with a minimum alternative exon
score of 2 and a maximum absolute gene expression
change of 3 because alternative splicing is a less critical
factor among highly DEGs (File S1, Table S14).
Gene expression data, complete lists of DABG p-values,
DEGs and alternative splicing events have been deposited
in the Gene Expression Omnibus (GEO) database
(Accession number: GSE53123).
4.7 Deriving cell-type-specific subnetworks
Transcriptomic data were mapped to the model in a manual
fashion (COBRA function: deleteModelGenes). Specifi-
cally, reactions dependent on gene products that were
called as ‘‘absent’’ were constrained to zero, such that
fluxes through these reactions were disabled. Submodels
were extracted based on the set of reactions carrying flux
(network pruning) by running fastFVA (Gudmundsson and
Thiele 2010) after mapping the metabolomic and
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transcriptomic data using the COBRA toolbox (Schellen-
berger et al. 2011).
4.8 Cell weight
We calculated the cell dry weight based on the relative
volume difference and comparison to human osteosarcoma
(U2OS) cells. The cell dry weight of U2OS cells, *60 pg
(Mir et al. 2011), and cell volume, 4,000 lm3 (Beck et al.
2011), were derived from the literature. The cell volume of
lymphocytes [243 lm3, the average volume of lymphoblasts
from patients with ALL, (Chapman et al. 1981)] was derived
from the literature. Cell dry weight was calculated accord-
ingly: 4,000/243 = 16.46, and 60 pg/16.46 = 3.645 pg
(3.645 9 1e-12 g).
4.9 Definition of maximum uptake rate and minimum
uptake rate
The maximum uptake rate was defined by the RPMI medium
concentrations, and the minimum uptake was defined by
mass spectrometry detection limits. Therefore, both medium
concentration (mM) and detection limit (mM) were con-
verted to flux values (mmol/gDW/h) by using a cell con-
centration of 2.17 9 1e6 (the concentration of viable CCRF-
CEM cells after 48 h), an experimental duration of 48 h, and
the calculated dry weight of 3.645 9 1e-12 g per cell:
Flux = MetConc/(CellConc 9 CellWeight 9 T 9 1,000).
In the case of uptake, they were defined by the RPMI medium
concentration (lower bound, lb) and the detection limit
(upper bound, ub), and in the case of secretion, they were
defined by the detection limit (lb) or left unconstrained (ub).
4.10 Setting general and qualitative exo-metabolomic
constraints during model building
Medium concentration to flux calculations were based on
3.645 9 1e-12 g cell weight, an initial cell concentration
of 2.17 9 1e6, T = 48 h, and Flux = MetConc/(Cell-
Conc 9 CellWeight 9 T). We constrained the model by
enforcing minimal flux through exchange reactions for
secreted or uptaken metabolites in the correct directions
(qualitative constraints). In the case of uptake, the upper
bound of the corresponding exchange reaction was set to
the flux equivalent of the minimal detection limit (Paglia
et al. 2012a) using the same equation used for the con-
centrations in the medium. In the case of secretion, the
lower bound of the exchange was set to be the minimum
flux value based on the minimal detection limit (File S1,
Table S15). The biomass reaction was constrained in a
cell-line-specific manner. The experimental growth rate
was 0.035 h-1 for CCRF-CEM and 0.032 h-1 for Molt-4
(File S1, Table S16). Vmax and Vmin were set to allow
20 % deviation from the experimental growth rate in each
direction. Oxygen uptake was constrained to Vmin =
-2.346 mmol/gDW/h (Thiele et al. 2005). All infinite
fluxes were set to the maximum: -500/500 mmol/gDW/h.
Alanine and glutamine are the breakdown products of
GlutaMax in an external reaction. The model did not
account for these reactions. However, the glutamine con-
centration was used to calculate the uptake flux of gluta-
mine, which otherwise was not present in the medium. The
increase of both compounds therefore did not necessarily
reflect actual secretion by the cells, as it may have simply
reflected the breakdown of GlutaMax, although additional
secretion by the cells cannot be excluded. In the case of
glutamine and alanine, the model exchanges remained
unconstrained (qualitative and quantitative constraints)
because the actual cell behavior could not be derived from
the data, as it was overshadowed by accumulation resulting
from the breakdown of GlutaMax (File S1, Tables S2–S3).
Uptake of the conditionally essential amino acid cysteine
(of which adequate amounts may not be produced) was
enabled. Repeated profiling of the two cell lines supported
the uptake of these amino acids (unpublished data). All
other exchange reactions were constrained to zero, except
those for basic ions, basic medium compounds and essen-
tial amino acids.
4.11 Definition of quantitative constraints
The constraints on the exchange reactions defined during
model building were the same in both condition-specific cell
line models (Fig. 1D). For the analysis, we used the relative
quantitative differences of commonly uptaken or secreted
metabolites to further constrain the models (quantitative
constraints). The model of the cell line that secreted more in
the experiment was forced to secrete more by increasing the
lower bound of the respective exchange reaction. The new
lower bound was set to be proportionate to the difference in
metabolite secretion in the experimental data (Fig. 1D, C,
D). Accordingly, we decreased the lower bound of the model
for the cell line that showed less uptake of the influx
metabolites (Fig. 1D, A, B). For a list of the adjusted bounds,
see the supplementary material (File S1, Table S17). To
estimate the ratio for adjustment, we first calculated the fold
change (FC) of each metabolite in the medium and in each
cell line by comparing the zero and 48 h time points. Next,
we compared the FC values to generate a slope
(Slope = FCcelline/FCmedium) for each cell line. In the last
step, we calculated the slope ratios (Slope Ratio = slop-
eCCRF-CEM/slopeMOLT4), which were used for the
adjustments (Fig. 1D, colored x = Slope Ratio). Some
metabolite exchanges were not adjusted, including those of
phosphate and the essential amino acids histidine, L-cysteine,
valine, methionine, alanine, and glutamine. The additional
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quantitative bounds were established to get a closer match to
the phenotypes, so we refrained from adding constraints
based on data, which was inconclusive.
Glutamine and alanine were the breakdown products of
Glutamax, however instead of modeling the breakdown of
Glutamax, we did not constrain the bounds for these
compounds.
The ACHR sampler implemented in the COBRA tool-
box (Schellenberger et al. 2011) was used with 10,000
generated warm-up points, nFiles = 100, pointsPer-
File = 5,000, and stepsPerPoint = 2,500, and the cell-line
models were used as inputs.
4.12 Comparison of network utilization and DEGs/AS
The models shared a set of 1,907 reactions. We defined a
reaction as differently utilized if the median value calcu-
lated from the sampling points differed by more than 10 %.
The shared reaction set was divided into three groups: x
(reactions with median difference[10 % and higher in
CCRF-CEM cells) = 1,381, y (reactions with median dif-
ference[10 % and higher in Molt-4 cells) = 158, and z
(reactions with median difference\10 % and reactions
with opposite directionality in addition to loop reac-
tions) = 368. Loop reactions were defined by FVA with
the criteria minFlux = -500 and maxFlux = 500 (219
reactions in Molt-4, 220 reactions in CCRF-CEM).
4.13 Enzyme assays
Molt-4 and CCRF-CEM cells were grown as described
previously and harvested in the log growth phase. Cell
number, size, and viability (Trypan blue exclusion) were
determined by counting cells on a Countess automatic cell
counter (Invitrogen). Cells were collected by centrifugation
at 2019g for 5 min, washed once with PBS, and pelleted
again by centrifugation. The cells were then resuspended in
extraction buffer (0.1 M Tris, 2.5 mM EDTA, pH 7.75) to
yield 1 9 105 cells/lL. These cells were heated on a heat
block set to 100 C for 2 min, followed by cooling on ice.
Following centrifugation at 20,0009g, the supernatant
fraction (hereafter called the metabolite extract, ME) was
removed and stored at -80 C prior to biochemical assays.
ATP content was measured in 1009 diluted ME by using
the CellTiter-Glo kit (Promega) and a Spectramax M3
microplate reader. NAD? and NADH were measured in
59 diluted ME using the Amplite fluorometric NAD/
NADH ratio assay kit (AAT Bioquest) according to the
manufacturer’s instructions. NADP? and NADPH were
similarly measured by using the Amplite fluorometric
NADP?/NADPH ratio assay kit (AAT Bioquest). Oxi-
dized and reduced glutathione was measured similarly in
109 diluted ME by using the Amplite fluorometric GSH/
GSSG ratio assay kit (AAT Bioquest). ROS was evaluated
by using a modified ORAC assay based on a method
described by Ganske and Dell (2006). Briefly, 25 lL of
ME or 25 lL of the standard 6-hydroxy-2,5,7,8-tetra-
methylchroman-2-carboxylic acid (Trolox, Sigma) was
mixed with 150 lL of 10 nM fluorescein (Sigma) and
25 lL of 120 nM [2,20-azobis(2-methylpropionamidine)
dihydrochloride] (Sigma) in a transparent 96-well micro-
plate (Brandt). Following 15 s of mechanical shaking,
fluorescence (ex: 485 nm, em: 580 nm; 515 nm cutoff fil-
ter used for emission to improve signal) was monitored at
1-min intervals for 80 min at 37 C. ORAC values were
extrapolated from a Trolox standard curve by using Soft-
max Pro software and expressed as lmol of Trolox
equivalent (lmol T.E.)/1 9 106 cells. All biochemical
assay data shown represent triplicate averages, n = 2.
All calculations were performed by using TomLab cplex
linear solver and MATLAB.
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